key: cord-0686116-5er5ec7r authors: Li, Y.; Lai, D.-y.; Zhang, H.-n.; Jiang, H.-w.; Tian, X.-l.; Ma, M.-l.; Qi, H.; Meng, Q.-f.; Guo, S.-j.; Wu, Y.-l.; Wang, W.; Yang, X.; Shi, D.-w.; Dai, J.-b.; Ying, T.-l.; Zhou, J.; Tao, S.-c. title: Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients date: 2020-06-09 journal: nan DOI: 10.1101/2020.06.07.20125096 sha: 2f99f8fc24a965b06267e25dbfbb5b94b76eebc7 doc_id: 686116 cord_uid: 5er5ec7r ARS-CoV-2 outbreak is a world-wide pandemic. The Spike protein plays central role in cell entry of the virus, and triggers significant immuno-response. Our understanding of the immune-response against S protein is still very limited. Herein, we constructed a peptide microarray and analyzed 55 convalescent sera, three areas with rich linear epitopes were identified. Potent neutralizing antibodies enriched from sera by 3 peptides, which do not belong to RBD were revealed. COVID-19 is caused by SARS-CoV-2 1,2 . By June 8th, 2020, globally, 7,007,948 diagnosed cases, 402,709 deaths were reported (https://coronavirus.jhu.edu/map.html) 3 . High titer of Spike protein (S protein) specific antibodies is in the blood of COVID-19 patients, especially IgG for both SARS-CoV 4 and SARS-CoV-2 5, 6 . Because of the central role that S protein plays in the entry of virus to the host cell, S1 and more specific, RBD (Receptor Binding Domain) is the most-focused target for the development of COVID-19 therapeutic antibodies 7, 8 and vaccines 9 . It is known that besides RBD, other areas/ epitopes of S protein may also elicit neutralization antibodies 10 . However, antibody responses to full length S protein at epitope resolution has not been investigated and the capability of linear epitopes to elicit neutralizing antibody is still not explored. To precisely decipher the B cell linear epitopes of S protein, we constructed a peptide microarray. A total of 211 peptides (Extended Data Table 1 ) were synthesized and conjugated to BSA. (Extended Data Fig.1a-c) . The conjugates along with control proteins were printed in triplicate, and with three dilutions. High reproducibility among triplicated spots or repeated arrays for serum profiling were achieved (Extended Data Fig.1d-e) . The peptides with variant concentrations may enable dynamical detection of antibody responses and indicate the antibodies against different epitopes may have different kinetic characteristics (Extended Data Fig.1f, Extended Data Fig.2a) . Moreover, inhibitory assay using free peptides verified the specificity of the signals generated against the peptides (Extended Data Fig.2b) . Fifty-five sera from convalescent COVID-19 patients and 18 control sera (Extended Data Table 2 ) were screened on the peptide microarray for both IgG and IgM responses ( Fig. 1a and Extended Data Fig. 3) . For IgG, COVID-19 patients were completely separated from controls, distinct and specific signals were shown for some peptides. In contrast, it was not distinct enough for IgM responses. We then focused on IgG for further analysis. Epitope map of S protein were generated based on the response frequency ( Fig.1b) . Majorly, there are three hot epitope areas across S protein. The first is on CTD (C Terminal Domain) that immediately follows RBD, i.e. from S1-93 to S1-113. Interestingly, the identified epitopes, S1-93, 97, 100/101, 105/106, 111 and 113 locate predominantly at flexible loops (Fig. 1c) . In addition, the signals of some epitopes had moderate correlations with others (Fig. 1e) , and most of these epitopes were positively correlated with S1 (Extended Data Fig. 4c-f . The second hot area is from S2-14 to S2-23, including the FP (Fusion Peptide, aa788-806) region and the S2'cleave site (R815) (Fig. 1d) . In contrary to the first hot region, the antibody responses against epitopes of this region had poor correlations among each other (Fig. 1f) , possibly due to the capability of this region to generate continuous but competitive epitopes. Moreover, part of this area is shielded by other parts in trimeric S (Fig. 1d) , suggesting this part would be easily accessed by immune system after the depart of S2 from S1. The third hot area is S2-78 or aa1148-1159, connecting HR1 (Heptad Repeat 1) and HR2 (Heptad Repeat 2) on S2 subunit. IgG antibodies against this epitope can be detected in about 90% COVID-19 patients, indicating it is an extremely dominant epitope. Except for these three areas, S2-34 (aa884-895) and S2-96/97 (1256-1273) also elicited antibodies in some patients. Overall, the epitope pattern of SARS-CoV-2 S protein is similar to that of SARS-CoV 11 (Fig. 1g) . RBD can elicit high titer of antibodies and highly correlates with that of S1 protein 6 (Extended Data Fig.4a) , suggesting RBD is a dominant region. A peptide, S1-82, locates exactly on the surface of RBM (Receptor Binding Motif) (Extended Data Fig 5a) , was identified as an epitope. However, further analysis demonstrated that the epitope had a poor specificity (Fig. 2a, Extended Data Fig 5a) , probably due to the sequence similarity (Extended Data Fig.5c-g) . Thus the validity of epitope S1-82 may need further investigation. Besides S1-82, no significant binding was observed for the rest of peptides locate at RBD, suggesting that conformational epitopes are dominant for RBD. Besides RBD, other areas/ epitopes of S protein may also elicit neutralization antibodies 10 . To explore this possibility, we chose 6 representative epitopes, i.e. S1-82, S1-93, S1-105, S1-113, S2-22 and S2-78 to test (Fig. 2a) . Antibodies that specifically bind these epitopes were separately enriched from five sera. High specificity of these antibodies, except for S1-82, were demonstrated (Fig. 2b, Extended Data Fig.6) . Pseudotyped virus neutralization assay with the enriched antibodies was then performed. Because of the limited amount of the enriched epitope-specific antibodies, the assay was performed for only a single point with the highest antibody concentration that was applicable for each epitope-specific antibody. Surprisingly, the antibodies against three epitopes, i.e., S1-93, S1-105 and S2-78 exhibited potent neutralizing activity with a 51%, 35%, 35% virus infection inhibitory efficiency at 8.3, 10.4 and 21 g/mL, respectively (Fig. 2c) . While not for S1-82, S1-113 and S2-S1-93 locates at CTD of S1. The antibody against this epitope has neutralizing activity, which is consistent with a recent study 12 , antibody binds this epitope may affect the conformation change of S for ACE2 binding. S1-105 also belongs to the CTD but close to the S1/S2 cleavage site. The antibodies may block effective protease cleavage on this site, which is critical for the entry of the virus. S2-78 locates adjacent to HR2, antibodies bind . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 9, 2020. . to this epitope may interfere the formation of 6-HB (Helical Bundle), an essential structure for cell membrane fusion 13 . Potent neutralizing antibodies could provide therapeutic and prophylactic reagents to fight against the COVID-19 pandemic 11 . However, it is risky to only focus on the RBD region, evolutionary pressure on this "hot" area may cause potential mutations in this region. This may by pass or defect the effectiveness of the RBD region centered therapeutic antibodies and vaccines in the developing pipeline 14 . Thus identification of other domains or epitopes that can elicit neutralizing antibodies is essential as well. Combination of the potent antigenicity of these peptides and neutralizing activity of the corresponding antibodies makes these epitopes potential candidates for both therapeutic antibodies and vaccine development. There are some limitations in this study. Because of very limited amount of purified antibodies could be enriched from valuable serum samples, we cannot perform a full set of neutralization assay by serial dilution to obtain the exact IC50. The IC50 estimated based on present data was 5-. However, monoclonal antibodies presumably have a better neutralization activity, so it is an option to acquire the reactive B cell clone and express recombinant monoclonal antibodies 2, 7 . Because of the poor availability of the convalescent sera, we did not thoroughly examine all the peptides that may potentially raise neutralizing antibodies. The other epitopes raised antibodies may also have neutralizing activities, such as S1-97, which is very closed to S1-93, or the peptides derived from the FP region, such as S2-18,19,20, which worth further investigation. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 9, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint Peptides were sequentially printed and the peptides for each row are indicated on the right. A representative merged image of one COVID-19 serum. IgG response is indicated as . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint green, while IgM is indicated as red. d-f. Correlations between repeated spots of the same protein on the same array, repeats arrays and peptide groups with different concentrations. Fig. 2 . Detection of the SARS-CoV-2 specific antibody responses by using the peptide microarray. a. Dynamic change of signal intensities for some representative peptides and S1 protein in different concentrations. b. Microarray results of the competition assays with the addition of free peptides to the sera. The serum used and the dilution are labeled above. The peptides used for competition are labeled on the left and the red arrows and white rectangles indicate the position of the corresponding peptides. Heatmap of IgM antibody responses of 55 sera from COVID-19 convalescent patients and controls (Healthy donors and Lung cancer patients). Peptides that fully cover S protein were surveyed and S1 protein and RBD were included on the peptide microarray as controls. The peptides were sequentially arranged without clustering. FI, fluorescent intensity. Fig.4 . Correlation analysis among antibody responses against S1 subunit derived epitopes and S1 protein. a-e. Correlations of IgG responses between two peptides, proteins or peptide and proteins. f. Summary of the correlations of IgG responses between representative peptides and S1 protein. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint Extended Data Fig.5 . Cross-activity of anti-S2-82 antibodies. a. The structural position of S1-82 on S protein (PDB: 6xyb). b. IgM responses of S1-82 in COVID-19 patients (blue) and controls (yellow). c-f. correlations of IgG responses between S1-82 and other peptides. The red spots were samples with high IgG signals for S1-82. g. Sequence similarity among the indicated peptides with S1-82. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. The peptide-BSA conjugates as well as S1 protein, RBD protein and N protein of SARS-CoV-2, along with the negative (BSA) and positive controls (anti-Human IgG and IgM antibody), were printed in triplicate on PATH substrate slide (Grace Bio-Labs, Oregon, USA) to generate identical arrays in a 1 x 7 subarray format using Super Marathon printer (Arrayjet, UK). The microarrays were stored at -80°C until use. The Institutional Ethics Review Committee of Foshan Fourth Hospital, Foshan, China approved this study and the written informed consent was obtained from each patient. COVID-19 patients were hospitalized and received treatment in Foshan Forth hospital during the period from 2020-1-25 to 2020-3-8 with variable stay time (Extended data . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint The neutralization assay was performed as described 3 Signal Intensity was defined as the median of the foreground subtracted by the median of background for each spot and then averaged the triplicate spots for each peptide or protein. IgG and IgM data were analyzed separately. Pearson correlation coefficient between two proteins or indicators and the corresponding p value was calculated by SPSS software . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint under the default parameters. Cluster analysis was performed by pheatmap package in R 4 . To calculate the response frequency of each epitope specific antibody, mean signal + 3*SD of the control sera were used to set the threshold. The epitope map was generated by ImmunomeBrowser issued by IEDB (Epitope Prediction and Analysis Tools) 5 . Visualization of the structural details were processed by Pymol (https://pymol.org/2/). The peptide microarray data are deposited on Protein Microarray Database (http://www.proteinmicroarray.cn) under the accession number PMDE242. Additional data related to this paper may be requested from the authors. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint NC65 NC66 NC96 NC97 NC63 NC98 LC174 NC64 LC171 LC175 NC95 LC182 LC168 NC67 LC177 LC181 LC169 LC180 501 401 432 610 531 730 510 416 4371 5333 419 528 4022 530 522 436 4021 520 529 410 5222 502 408 15 727 407 11 14 508 744 607 414 533 13 S1-93 S1-97 S1-100 S1-101 S1-105 S1-106 S1-111 S1-113 S1-93 S1-97 S1-100 S1-101 S1-105 S1-106 S1-111 S1-113 f. Patients S1-1 S1-11 S1-20 S1-30 S1-41 S1-50 S1-60 S1-70 S1-82 S1-93 S1-100 S1-113 N-glycosylation sites . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . antibodies. a. S1 RBD S1-82 S1-93 S1-105 S1-113 Anti-S1-93 Anti-S1-105 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint Control Control Control Buffer S1-1-S1-64 S1-65-S1-114, S2-1-S2-10 S2-11-S2-74 S2-75-S2-97, Controls 0.9 mg/mL 0.3 mg/mL 0.1 mg/mL F. Extended Data Fig.1 Peptide design and preparation Layout of the peptide microarray Representative microarray image of COVID-19 patient serum profiling . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. Signal Intensity Serum dilution S1 subunit 0.5 mg/mL 0.17 mg/mL 0.056mg/mL . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint S1-1 S1-11 S1-20 S1-30 S1-41 S1-50 S1-60 S1-70 S1-82 S1-93 S1-100 S1-113 S2-10 S2-20 S2-30 S2-40 S2-50 S2-60 S2-70 S2-78 S2-97 NC67 NC66 NC97 NC63 NC64 520 19 528 NC98 NC65 LC169 LC182 17 LC174 NC96 534 415 531 NC95 744 414 14 607 15 13 LC177 LC180 407 527 522 405 11 404 410 436 409 4022 508 16 LC175 LC181 510 526 605 5222 429 533 406 509 501 416 4371 432 532 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. Extended Data Fig.4 . Correlation analysis among antibody responses against S1 subunit derived epitopes and S1 protein. RBD vs. S1 protein RBD vs. S1-82 S1 protein vs. S1-93 S1 protein vs. S1-105 0 2,000 4,000 6,000 8,000 10,000 0 20,000 40,000 S1-111 S1 protein E. S1 protein vs. S1-111 r=0.733 p<0.001 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. G. Sequence similarity to S1-82 Extended Data Fig.5 . Cross-reactivity of anti-S2-82 antibodies . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint S1-113 S1-113 S1-105 S1-105 S2-78 S2-78 S2-22 S2-22 S1-93 S1-93 S1-82 S1-82 S1-113 A. Probe the enriched antibodies on the peptide array Anti-S1-113 Anti-S1-22 Anti-S1-82 S1-1-S1-32 S1-33-S1-64 S1-65-S1-96 S1-97-S1-114; S2-1-S2-10 S2-11-S2-42 S2-43-S2-74 S2-75-S2-97 Control B. Layout of the peptide microarray V 2.0 C. Comparison of sera before and after depletion of epitope specific antibodies Extended Data Fig.6 . Epitope-specific antibody depletion from sera RBD . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint NO. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 9, 2020. . https://doi.org/10.1101/2020.06.07.20125096 doi: medRxiv preprint A pneumonia outbreak associated with a new coronavirus of probable bat origin A new coronavirus associated with human respiratory disease in China An interactive web-based dashboard to track COVID-19 in real time Profile of specific antibodies to the SARS-associated coronavirus Antibody responses to SARS-CoV-2 in patients with COVID-19 Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells Identification of Human Single-Domain Antibodies against SARS-CoV-2 A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein References 1. National Health Commission & National Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma Identification of Human Single-Domain Antibodies against SARS-CoV-2 Pretty Heatmaps ImmunomeBrowser: A tool to aggregate and visualize complex and heterogeneous epitopes in reference proteins S1-72 427 DDFTGCVIAWNS 438 Failure for synthesis 73 S1-73 433 VIAWNSNNLDSK 444 74 S1-74 439 NNLDSKVGGNYN 450 75 S1-75 445 VGGNYNYLYRLF 456 Insoluble 76 S1-76 451 YLYRLFRKSNLK 462 77 S1-77 457 RKSNLKPFERDI 468 78 S1-78 463 PFERDISTEIYQ 474 79 S1-79 469 STEIYQAGSTPC 480 80 S1-80 475 AGSTPCNGVEGF 486 81 S1-81 481 NGVEGFNCYFPL 492 82 S1-82 487 NCYFPLQSYGFQ 498 83 S1-83 493 QSYGFQPTNGVG 504 84 S1-84 499 PTNGVGYQPYRV 510 85 S1-85 505 YQPYRVVVLSFE 516 86 S1-86 511 VVLSFELLHAPA 522 87 S1-87 517 LLHAPATVCGPK 528